Trevi Therapeutics, Inc. (TRVI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TRVI currently has 146M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 79.8% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 145.6M shares outstanding |
150M | 0 |
| Mar 17, 2026 |
10-K filing | 134.7M shares outstanding |
130M | 0 |
| Nov 13, 2025 |
10-Q filing | 128.2M shares outstanding |
130M | 0 |
| Aug 07, 2025 |
10-Q filing | 130.4M shares outstanding |
130M | 0 |
| May 08, 2025 |
10-Q filing | 101.7M shares outstanding |
100M | 9.1M |
| Mar 18, 2025 |
10-K filing | 102.0M shares outstanding |
100M | 8.8M |
| Nov 06, 2024 |
10-Q filing | 76.9M shares outstanding |
77M | 34M |
| Aug 08, 2024 |
10-Q filing | 72.6M shares outstanding |
73M | 38M |
| May 07, 2024 |
10-Q filing | 70.4M shares outstanding |
70M | 40M |
| Mar 20, 2024 |
10-K filing | 69.0M shares outstanding |
69M | 42M |
| Nov 09, 2023 |
10-Q filing | 63.9M shares outstanding |
64M | 47M |
| Aug 11, 2023 |
S-3/A filing: The company may offer and sell securities from time to time in one or more offerings of up to $200,000,000 in aggregate offering price. |
64M | 47M |
| Aug 10, 2023 |
10-Q filing | 63.9M shares outstanding |
64M | 16M |
| Jun 29, 2023 |
S-3 filing: The company is filing an S-3 to offer debt securities, common stock, and preferred stock from time to time in one or more offerings of up to $200,000,000 in aggregate offering price. They also entered into a sales agreement with SVB Securities LLC, relating to shares of their common stock, par value $0.001 per share, offered by this prospectus, with an aggregate offering price of up to $75,000,000. |
60M | 19M |
| May 11, 2023 |
10-Q filing | 60.1M shares outstanding |
60M | 19M |
| Mar 16, 2023 |
10-K filing | 64.5M shares outstanding |
65M | 15M |
| Nov 10, 2022 |
10-Q filing | 59.9M shares outstanding |
60M | 19M |
| Aug 11, 2022 |
10-Q filing | 42.8M shares outstanding |
43M | 37M |
| May 12, 2022 |
10-Q filing | 38.7M shares outstanding |
39M | 41M |
| May 02, 2022 |
S-3 filing: This prospectus relates to the resale from time to time of up to an aggregate of 28,960,199 shares of common stock of Trevi Therapeutics, Inc. by the selling stockholders. |
4.6M | 75M |
| Mar 17, 2022 |
10-K filing | 30.8M shares outstanding |
31M | 20M |
| Nov 10, 2021 |
10-Q filing | 25.8M shares outstanding |
26M | 25M |
| Nov 05, 2021 |
S-3 filing: This S-3 filing relates to the resale of up to 5,555,556 shares of common stock of Trevi Therapeutics, Inc. by the selling stockholder, including shares issuable upon the exercise of outstanding warrants. |
22M | 29M |
| Oct 15, 2021 |
S-3 filing: This prospectus relates to the resale from time to time of up to 21,897,810 shares of common stock of Trevi Therapeutics, Inc. by the selling stockholder. |
22M | 23M |
| Oct 08, 2021 |
RW filing: This is a request for the withdrawal of the Registration Statement on Form S-1 (File No. 333-259120) originally filed on August 27, 2021, in connection with the proposed public offering of common stock, which the company has decided not to pursue. |
22M | 1.4M |
| Aug 27, 2021 |
S-1 filing: This S-1 filing registers shares of common stock for offering, including an underwriter option to purchase additional shares. |
22M | 1.4M |
| Aug 12, 2021 |
10-Q filing | 21.6M shares outstanding |
22M | 1.4M |
| Jul 07, 2021 |
S-1 filing: This prospectus relates to the resale, from time to time, of up to 5,170,088 shares of our common stock, par value $0.001 per share, by the selling stockholder, Lincoln Park Capital Fund, LLC. |
20M | 3.1M |
| May 13, 2021 |
10-Q filing | 19.9M shares outstanding |
20M | 0 |
| Mar 25, 2021 |
10-K filing | 19.9M shares outstanding |
20M | 0 |
| Nov 12, 2020 |
10-Q filing | 18.4M shares outstanding |
18M | 0 |
| Aug 13, 2020 |
10-Q filing | 18.2M shares outstanding |
18M | 0 |
| Jun 26, 2020 |
S-3 filing: Trevi Therapeutics, Inc. files an S-3 form for a shelf offering of Debt Securities, Common Stock, and Preferred Stock with a total proposed amount of $150,000,000. They also filed for Common Stock with a total proposed amount of $12,000,000. They may offer and sell securities from time to time in one or more offerings. |
18M | 0 |
| May 07, 2020 |
10-Q filing | 17.8M shares outstanding |
18M | 0 |
| Mar 16, 2020 |
10-K filing | 17.8M shares outstanding |
18M | 0 |